Micromanagement of Lymphomas by Arpaia, Enrico & Mak, Tak W
PLoS Biology  |  www.plosbiology.org PLoS Biology  |  www.plosbiology.org 1144 June 2008  |  Volume 6  |  Issue 6  |  e156
L
ymphomas are tumours composed of lymphocytes. 
The two types of lymphocytes—T cells and B cells—
are distinguished by the antigen receptors on their 
surfaces and the specific functions they undertake on behalf 
on the immune system. Precursors of B cells are generated in 
the bone marrow and leave only after they have undergone 
a genetic rearrangement of the DNA encoding the protein 
chains that compose the functional B cell receptor (BCR). 
Each BCR binds a specific antigen, and if it is a foreign 
antigen (i.e., from an invading pathogen), that specific B 
cell undergoes division to produce many identical progeny 
(clonal amplification) that will later produce antibodies, 
which are the secreted form of the BCR present on the cell 
surface. 
 Normal pre-B lymphocytes are developmentally 
programmed to undergo apoptosis (Bcl-2 gene expression, 
which results in survival, is down-regulated in these cells). 
However, the expression of a functional BCR leads to 
signalling that up-regulates Bcl-2 expression and rescues 
these cells such that they relocate in the peripheral blood 
and become mature B cells [1–4]. Therefore, during 
development, B cells are continuously under selective 
pressure to express functional BCRs. This implies the 
existence of a basic BCR-mediated signal that provides 
maintenance of the B cell homeostasis [5]. The nature of 
this constitutive signal is distinct from an antigen-driven 
signal that leads to proliferation and clonal expansion of the 
mature B cells, and therefore it is better defined as a basal, or 
“tonic”, signal [6–8]. However, a mechanistic understanding 
of this survival tonic signal is still lacking. Perhaps B cells 
require constitutive low-level receptor engagement with low-
affinity autoantigens for survival [9]. Conversely, the tonic 
signal could be the result of a steady-state level of signalling 
in unstimulated cells, generated by an equilibrium between 
positive and negative regulators downstream of the BCR [8]. 
Certainly, the specific signalling pathway initiated by the BCR 
to sustain pre-B cells is still elusive, and it remains debatable 
whether the receptor signals autonomously or requires 
activation by antigen. 
Role for the BCR in Lymphoma Induction—The 
Evidence 
One fascinating aspect of BCR signalling is its potential 
involvement in lymphomagenesis. Many B cell lymphomas 
are caused by reciprocal chromosomal translocations that 
result in an oncogene coming under the control of an active 
antibody (immunoglobulin, Ig) gene locus. Deregulated 
oncogene expression then leads to constitutive transcription/
translation and eventually transformation of the cell to a 
cancerous state. The fact that most B cell lymphoma cells 
express a functional BCR raises several interesting questions. 
Is the BCR required for lymphomagenesis? Does the BCR 
contribute to tumour cell proliferation? Does a tonic signal or 
an encounter with its matching (cognate) antigen augment 
BCR signalling leading to lymphomagenesis? 
In a new PLoS Biology study, Refaeli et al. ask precisely 
these questions and present evidence (summarized in Table 
1) that the BCR plays a pivotal role in lymphomagenesis [10]. 
To reach their conclusions, Refaeli et al. took advantage 
of EµMYC mice, which bear a transgene expressing the 
MYC oncogene under the control of the enhancer (µ) 
in the IgH locus.  EµMYC mice have long been known to 
develop clonal tumours of pre-B or B cells [11,12]. Refaeli 
et al. generated a series of derivative EµMYC transgenic 
mice. Table 2 summarizes the characteristics of these mice. 
When Refaeli et al. characterized the tumours developing 
in these mutant strains, they found that EµMYC/sHEL mice 
developed lymphomas at the same rate as EµMYC mice. 
Thus, the continuous presence of a specific antigen (hen egg 
lysozyme (HEL)) alone does not alter the cancer phenotype 
of the mice. Intriguingly, the introduction of BCRHEL alone 
accelerated the onset of lymphomas compared to the rate of 
onset in EµMYC and EµMYC/sHEL mice. The introduction 
of BCRHEL concomitant with continuous production of 
the HEL antigen produced a further acceleration of 
lymphomagenesis compared to EµMYC/BCRHEL mice. These 
data clearly demonstrate that the BCR can cooperate with 
the MYC oncogene to accelerate lymphomagenesis, and that 
this acceleration is increased when the BCR is stimulated by 
cognate antigen. Thus, a possible interpretation of the data is 
that the presence alone of a specific BCR (BCRHEL) seems to 
intensify the effect of the tonic signal and, when the specific 
BCRHEL and its cognate sHEL antigen are present, the tonic 
signal becomes a full strength signal.
Curiously, different derivative EµMYC strains developed 
different types of tumours. Figure 1 depicts the cellular 
derivation of these tumours. Lymphomas of EµMYC mice 
are characteristically pre/pro-B cell in nature, but the 
tumours in EµMYC/ BCRHEL mice contained more mature 
but naive CD5– cells. In chronic lymphocytic leukemia 
(CLL) approximately 95% of the cells express a B-phenotype 
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(B-CLL) and express the CD5 antigen. However, among 
B CLL, 7%–20% are CD5– [13]. The significance of the 
absence of CD5 expression in these cells is unclear; however, 
CLL with low expression of CD5 should be regarded as a 
subtype of CLL [13]. Therefore, the tumours in EµMYC/ 
BCRHEL should be classified as CLL. In contrast, EµMYC/
BCRHEL/sHEL mice developed tumours similar to Burkitt 
lymphomas. Another surprising difference was that, although 
lymphomas of EµMYC mice were largely monoclonal in 
nature, the tumours isolated from EµMYC/BCRHEL, EµMYC/
BCRHEL/sHEL, and MMTV-rtTA/TRE-MYC/BCRHEL/sHEL 
mice were polyclonal. For example, EµMYC/BCRHEL and 
EµMYC/BCRHEL/sHEL exhibited 20–40 clones and 10–15 
clones, respectively. This is somewhat surprising because 
EµMYC tumours are monoclonal, and human B lymphomas 
are generally monoclonal [14,15]. In fact, clonality can be 
clinically used to distinguish between a chronic inflammatory 
hyperproliferation and a neoplasm [15]. 
How the introduction of a specific BCR repertoire in the 
EµMYC background leads to multiclonality is not clear. The 
question arises as to whether the lymphoma is a true tumour or 
if it is the result of excessive proliferation. However, tumours 
from all of the derivative EµMYC mutants were transplantable 
into recipient mice. This demonstrates that indeed the donor 
cells were tumour cells. These transplantation experiments 
showed that antigen stimulation of the BCR is required for 
B cell transformation. Mice transgenic for MMTV-rtTA/
TRE-MYC/BCRHEL did not develop tumours if they were 
treated with doxycycline to repress MYC expression. When the 
sHEL-recognizing B cells from these mice were transplanted 
into C57/B6 recipients, tumours did not develop even in the 
absence of doxycycline (when the MYC gene is expressed 
constitutively) due to the lack of sHEL expression. However, 
when these same cells were transplanted into HEL-expressing 
mice, tumours readily appeared. Furthermore, these tumours 
were transplantable in HEL-expressing animals but not in 
wild-type animals, even in the absence of doxycycline. Refaeli 
et al. also noted that tumour cells from either EµMYC/
BCRHEL/sHEL or MMTV-rtTA/TRE-MYC/BCRHEL/sHEL mice 
generated lethal tumours in recipients that did not express 
the HEL antigen, but this was attributed to the expression of 
the HEL transgene by the transplanted tumour cells. These 
in vivo experiments clearly support the notion that both 
expression alone of the BCR, as well as BCR binding to its 
cognate antigen, are required to promote lymphomagenesis. 
Interestingly, these two mechanisms appear to operate 
independently, because EµMYC/BCRHEL and EµMYC/
BCRHEL/sHEL mice develop different types of tumours. 
A Block in BCR Signalling Blocks Lymphoma 
Generation
Another experiment supporting the requirement for BCR 
signalling in lymphomagenesis involved the silencing of 
signalling components of the BCR—Igα/Igβ. Tumours 
isolated from EµMYC/BCRHEL mice were transduced 
with lentivirus encoding shRNA directed against either 
Igα or Igβ. The transduced tumour cells were then 
transplanted into Rag–/– mice that were incapable of any T 
cell responses to the virus (and thus also incapable of any 
T-dependent B cell responses). In the absence of Igα/Igβ 
signalling, the transplanted tumours failed to expand in the 
immunodeficient recipients. This result not only confirms the 
role of BCR signalling in lymphomagenesis but also implies 
that continuous signalling by the BCR is required for the 
tumour to thrive.
Table 1. Phenotypes of EµMYC derivative strains created by Refaeli et al.
Genotype Clonality Lymphoma Type Cell Surface Markers Sensitivity to 
Immunosuppressants
Sensitivity to Alkylating 
Agents
EµMYC Monoclonal Pre/Pro-B cell B220, CD19, CD5 None Cyclophosphamide
EµMYC/BCRHEL Polyclonal CD5- B-CLL–like B220, CD19, CD21, CD23, IgM, 
BCRHEL 
Cyclosporine A Cyclophosphamide
EµMYC/BCRHEL/sHEL Polyclonal Burkitt-like B220, CD19, CD21, PNA, B7-2, 
CD69, IgM, BCRHEL
Cyclosporine A, FK506, 
Rapamycin
Cyclophosphamide
MMTV-rtTA/TRE-MYC/
BCRHEL/sHEL
Polyclonal Burkitt-like B220, CD19, CD21, PNA, B7-2, 
CD69, IgM, BCRHEL
Cyclosporine A, FK506, 
Rapamycin
Cyclophosphamide
doi:10.1371/journal.pbio.0060156.t001
Table 2. EµMYC-Derived Transgenic Strains
Genotype of Transgenic Mice 
Strains
Control of MYC Gene  
Expression
Phenotype Survival (wk)
EµMYC µ enhancer of the IgH locus Parental strain 32
EµMYC/sHEL µ enhancer of the IgH locus Expresses a soluble HEL (hen egg lysozyme) antigen 32
EµMYC/BCRHEL µ enhancer of the IgH locus Expresses a HEL-specific BCR repertoire 22
EµMYC/BCRHEL/sHEL µ enhancer of the IgH locus Expresses a HEL-specific BCR repertoire and the soluble HEL antigen 12
MMTV-rtTA/TRE-MYC/BCRHEL Doxycycline-repressable promoter Expresses a HEL-specific BCR repertoire 12
MMTV-rtTA/TRE-MYC/BCRHEL/sHEL Doxycycline-repressable promoter Expresses a HEL-specific BCR repertoire and the soluble HEL antigen 12
The µ enhancer of the IgH locus controls constitutively the expression of the MYC gene. The doxycycline-repressible promoter can be turned on or off depending on the presence of 
doxycycline in the diet of the mice. In the presence of doxycycline, the promoter controlling the MYC gene expression is turned off. These mice in the presence of doxycycline do not 
develop tumours. The advantage of using a repressible promoter is that the expression of the MYC gene can be turned off by simply removing doxycycline from the diet of the animals. 
The survival data correspond to 50% surviving mice. 
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If BCR signalling is truly crucial for the formation of 
tumours in EµMYC/BCRHEL, EµMYC/BCRHEL/sHEL, and 
MMTV-rtTA/TRE-MYC/BCRHEL/sHEL mice, then these 
lymphomas should be sensitive to immunosuppressive drugs 
that block the BCR signalling pathway at particular points. 
Refaeli et al. transplanted recipient mice with tumours from 
the derivative EµMYC strains and treated these recipients 
with the immunosuppressants cyclosporine A, FK506, and 
rapamycin. They then compared tumour growth in these 
animals with growth in tumour-transplanted recipients 
treated with the more general inhibitor cyclophosphamide. 
Cyclosporine A is thought to bind to the cytosolic protein 
cyclophilin expressed by all immunocompetent lymphocytes. 
This cyclosporine A/cyclophilin complex inhibits 
calcineurin, which normally activates interleukin-2 (IL-2) 
transcription and sustains effector T cell functions. FK506 
reduces peptidyl-prolyl isomerase activity by binding to 
the immunophilin FKBP-12, creating a new complex. This 
FKBP-12/FK506 complex also interacts with and inhibits 
calcineurin, again blocking IL-2 transcription. Rapamycin 
binds to cytosolic FKBP-12 in a manner similar to FK506 but 
forms a rapamycin/FKBP-12 complex that binds directly 
to mTOR complex 1, disrupting the mammalian target 
of rapamycin (mTOR) pathway. Lymphocyte responses 
to IL-2 are thus decreased, and T and B cell activation 
is abrogated. In contrast to these signalling inhibitors, 
cyclophosphamide acts mainly on a cell’s DNA via the 
metabolite phosphoramide mustard, which forms lethal 
DNA crosslinks at guanine N-7 positions. In Refaeli et al.’s 
experiments, the growth of tumours in EµMYC mice was 
inhibited only by cyclophosphamide. However, tumours 
in EµMYC/BCRHEL mice responded to either cyclosporine 
A or cyclophosphamide. Tumours in EµMYC/BCRHEL/
sHEL and MMTV-rtTA/TRE-MYC/BCRHEL/sHEL mice 
responded to all immunosuppressive drugs tested as well as 
to cyclophosphamide. It is not clear why EµMYC/BCRHEL and 
EµMYC/BCRHEL/sHEL or MMTV-rtTA/TRE-MYC/BCRHEL/
sHEL tumours respond differently to immunosuppressants. 
However, BCR signalling definitely drives some lymphomas, 
and the signalling emanating from an unoccupied BCR may 
be different from that triggered by a BCR engaged by cognate 
antigen. 
The Tonic/Full-Strength BCR Signalling Hypothesis
It is not hard to imagine that BCR functions would be similar 
during normal B cell development and lymphomagenesis. 
Current theory holds that, in normal animals, the positive 
selection of mature B cells depends on BCR signalling. In 
addition, the BCR provides a weak but essential survival 
stimulus to a mature B cell in the periphery, while this cell 
is awaiting an encounter with cognate antigen. Non-cognate 
antigens that briefly and nonspecifically “tickle” the BCR may 
initiate a tonic signal that mediates survival.
However, it is not until BCR engagement by cognate 
antigen that the receptor delivers a full-strength signal to the 
B cell that leads to activation of the transcription factor NF-κB 
followed by proliferation and differentiation. A parallel series 
of events may occur during lymphomagenesis, as is illustrated 
by Refaeli et al.’s EµMYC-derivative mice. 
The exact identity of this tonic signal remains obscure. 
It may involve a trickle of survival signals from the 
phosphatidylinositol 3-kinase (PI3K), NF-κB, or BCL-2 
pathways.  Here, we postulate its existence and define it 
operationally. Basal activation of the diverse BCR repertoire 
of EµMYC mice may provide a tonic signal that can confer 
survival to the first transformed B cell. A similar kind of signal 
has been postulated to overcome the intrinsic homeostatic 
cell death mechanism mediated by cytochrome C release (a 
protein that is released by the mitochondria in response to 
pro-apoptotic signals) or death receptor engagement [16]. 
In the case of EµMYC/BCRHEL mice, the transgenic BCRHEL 
BCR appears to deliver an enhanced tonic signal. This signal 
attains full-strength in EµMYC/BCRHEL/sHEL mice when 
the BCR is engaged by cognate antigen. In all three types 
of mutants, when MYC expression becomes deregulated 
such that MYC is over expressed, the transformed B cell 
proliferates and starts to form a tumour (Figure 1). One 
puzzle that remains is why do EµMYC/BCRHEL mice exhibit 
accelerated lymphomagenesis in the absence of HEL antigen? 
It may be that the putative enhanced tonic signal delivered by 
the transgenic BCRHEL leads to prolonged or stronger NF-κB 
signalling, which in turn accelerates tumour cell proliferation. 
NF-κB can be activated in a myriad of signal- and cell-specific 
ways [17], and different pathways affect the intensity of the 
signal delivered.
A human example that is partially consistent with 
the tonic/full-strength BCR signalling hypothesis may 
be the development of MALT lymphomas, which are 
B cell malignanices in the mucosa-associated lymphoid 
tissues. Gastric lymphomas are thought to be initiated 
doi:10.1371/journal.pbio.0060156.g001
Figure 1. Cellular Derivation of the Lymphomas in EµMYC and 
EµMYC-Derived Mouse Strains
In Refaeli et al.’s experimental system [10], mice of different genotypes 
develop lymphomas at different stages of B cell maturation in response 
to different antigenic stimuli. EµMYC mice develop oligoclonal pre/
pro-B cell lymphomas in response to nonspecific antigens, generating 
a tonic signal that promotes survival (see text). EµMYC/BCRHEL mice 
express a transgenic BCR that mediates an enhanced tonic signal; these 
mice develop more mature polyclonal CLL-like lymphomas. B cells 
of EµMYC/BCRHEL/sHEL and MMTV-rtTA/TRE-MYC/BCRHEL/sHEL mice 
receive the most powerful “full-strength signal” when they encounter 
specific HEL antigen; these mutants develop polyclonal, more mature 
B cell lymphomas. In all these cases, tumorigenesis is dependent on 
the overexpression of MYC and on continuous BCR stimulation. The 
phenotype of the tumours developed correlates with the strength of the 
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by Helicobacter pylori infections that stimulate the 
hyperproliferation of B cells specific for H. pylori antigens. 
The chronic inflammation induced by persistent H. pylori 
infection may cause DNA damage leading to genetic 
abnormalities and the emergence of a neoplastic B clone. 
Three such genetic abnormalities are recurrent chromosomal 
translocations. T(11;18)(q21;q21) results in the expression of 
an API2-MALT1 fusion protein [18]. The API2 gene product 
is an apoptosis inhibitor, which inhibits the activity of caspase 
3, 7, and 9. T(1;14)(p22;q32) and T(14;18)(q32;q21) cause 
the BCL10 and MALT1 genes, respectively, to come under 
the control of the IgH locus, dysregulating their expression 
[18]. The BCL10 and MALT1 proteins are components of 
the antigen receptor signalling pathway that leads to NF-κB 
activation [17]. In early-stage gastric MALT lymphomas, 
tumour growth is stimulated by H. pylori antigens and 
direct CD40-mediated interaction between T and B cells 
[19]. However, when the translocated gene sequences are 
expressed, lymphoma growth becomes independent of H. 
pylori and BCR stimulation. The analogy between Refaeli et 
al.’s experimental system and MALT lymphomas lies in the 
fact that the BCR delivers survival signals to B cells that give 
rise to tumours. 
Future Directions
The BCR activates several signal pathways, including 
the phosphatidylinositol 3-kinase (PI3K) pathway 
[20]. However, the similarities between Refaeli et al.’s 
experimental system and MALT lymphomas suggest that 
BCL10 and NF-κB may be involved in the lymphomagenesis 
occurring in EµMYC/BCRHEL/sHEL and MMTV-rtTA/TRE-
MYC/BCRHEL/sHEL mice. Therefore, further investigation 
of this pathway may yield novel information on the 
relationship between immune responses and lymphomas. 
In addition, knowledge of the precise signalling pathway 
driving a particular lymphoma has the potential to improve 
treatment by allowing highly specific and effective therapies 
to be deployed.  
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